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Background: The purpose of this scoping review was to review the literature on healthcare provider provision of
anti-D prophylaxis to RhD negative pregnant women in appropriate clinical situations in various healthcare settings.
Methods: A scoping review framework was used to structure the process. The following databases were searched:
CINAHL (EBSCO), EBM Reviews (OvidSP), Embase (OvidSP), Medline (OvidSP), and Web of Science (ISI). In addition,
hand searching of article references was conducted. The search yielded 301 articles. Thirty-five articles remained for
review after screening. Two team members reviewed each article using a detailed data collection sheet. A third
reviewer was utilized if discrepancies occurred amongst reviewers.
Results: The review process yielded 18 included articles. The majority of the studies were conducted in the United
Kingdom. Of the 18 studies, 15 were retrospective studies. The articles were largely conducted in one institution. The
articles with a focus on routine antenatal provision of anti-D immunoglobulin found that it was given 80 to 90% of the
time. Postpartum provision of anti-D immunoglobulin had significantly higher results of 95-100%. The review found that
the delivery of anti-D immunoglobulin to RhD negative pregnant women during situations of potential sensitizing events
was suboptimal.
Conclusions: The included articles examine the management of RhD negative pregnancies in various countries with
existing national guidelines. The existing evidence indicates an opportunity for quality improvement in situations where
potential sensitizing events are not at routine times in pregnancy, such as miscarriage or fetal demise early in pregnancy.
Routine care for the prevention of RhD alloimmunization in pregnancy and postpartum appears to be fairly consistent.
The paucity of recent literature in this area leads to a recommendation for further research.
Keywords: RhD isoimmunization, practice guidelines, Rho(D) Immune Globulin, guideline adherence, anti-D
immunoglobulinBackground
RhD alloimmunization can lead to Hemolytic Disease of
the Fetus and Newborn (HDFN) or in severe cases fetal
demise [1]. This can occur if an RhD negative pregnant
woman has a sensitizing event during her pregnancy that
causes the development of anti-D antibodies [2]. These
antibodies work to destroy fetal red blood cells [1].
The prophylaxis for the prevention of RhD alloimmuni-
zation was developed in the 1960s [1]. Since its discovery,
anti-D immunoglobulin has remained the gold standard
in the prevention of RhD alloimmunization and conse-
quently HDFN [3]. However, this is under debate in the* Correspondence: trina.fyfe@unbc.ca
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unless otherwise stated.current literature [4]. Anti-D immunoglobulin is a blood
product given to RhD negative pregnant women during
pregnancy and after delivery. According to various guide-
lines, RhD negative women receive the prophylaxis at
28 weeks (and again at 34 weeks if the guideline indi-
cates a two dose regime) and again after the delivery of
an RhD positive fetus [5-10]. Outside of routine provision,
RhD negative pregnant women can receive anti-D im-
munoglobulin during pregnancy when potential sensitiz-
ing events occur. A list of potential sensitizing events can
be found in an additional file (see Additional file 1). Since
the development of anti-D immunoglobulin, the rate of
RhD alloimmunization and its consequences has been sig-
nificantly reduced but the cited RhD alloimmunization. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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improvement [11].
In 2012, two retrospective studies were published that
examined the delivery of anti-D immunoglobulin to RhD
negative pregnant women in appropriate clinical situa-
tions within emergency departments [12,13]. These two
studies found that in certain clinical situations the deliv-
ery of anti-D immunoglobulin to RhD negative pregnant
women was suboptimal. The recent emergence of these
two studies led the authors of this review to question
whether more research exists on the provision of prophy-
laxis to RhD negative pregnant women and if there are
settings besides emergency departments that contribute to
the RhD alloimmunization rate of 6.7/1000 births [11].
The purpose of this scoping review is to explore the
literature on the provision of anti-D prophylaxis to RhD
negative pregnant women in appropriate clinical situations
in various healthcare settings. The hypothesis is that RhD
negative pregnant women receive anti-D immunoglobulin
in routine situations, such as within 72 hours after birth,
but in situations of potential sensitizing events, such as
miscarriage or fetal demise, anti-D immunoglobulin may
not always be provided correctly or at all. To date, a know-
ledge synthesis has not been conducted on this topic.
Methods
A scoping review framework was chosen because it is an
exploratory process, enabling the team to determine the
depth, range, and nature of the research that exists, thereby
not limiting to specific types of research methodology and
critical analysis. This review followed Levac et al’s [14]
scoping review framework: identify the research ques-
tion, identify relevant studies, select the studies, chart the
data, summarize and report the results, and consult with
knowledge users. Ethics was not required because this re-
view methodology was not experimental research nor did
it involve human participants.
Data sources
The following databases were searched by a librarian:
CINAHL (EBSCO), EBM Reviews (OvidSP), Embase
(OvidSP), Medline (OvidSP), and Web of Science (ISI).
In addition to database searching the librarian hand
searched reference lists of potential articles to include.
To ensure rigor, the librarian had the database search
strategy peer reviewed by another librarian. This process
reduced the likelihood of human based search error [15].
The following search terms were used: Rho(D) Immune
Globulin, immunoglobulins, anti-idiotypic antibodies, anti-D
immunoglobulin, anti-D immune globulin, anti-D prophy-
laxis, anti-D immunoprophylaxis, Rhogam, Winrho,
pregnancy, pregnant women, Rh alloimmunization, Rh
sensitization, Rh isoimmunization, Rh incompatibility,
rhesus disease, blood group incompatibility, hospitalists,family physicians, emergency physicians, obstetricians,
nurse practitioners, midwifery, nurse midwives, hospital
emergency service, emergency department, acute care,
obstetrics and gynecology department, primary care, out-
posts, ambulatory care facilities, hospital units, or birthing
centres. Medical subject headings were used when avail-
able and deemed appropriate. Keyword searching utilized
truncation and alternative spelling.
Study selection
In order to explore the nature and size of the litera-
ture in this area the selection criteria for this synthesis
were broad. After the search was complete, the results
were combined and duplicates removed, the articles
were screened for relevancy. After the screening process,
two team members reviewed the full text of each article. A
data extraction sheet was used to compile data on each
article with the option of inclusion or exclusion. Reviewers
were asked to solve discrepancies amongst themselves but
in the event that they were unable to do this a third
reviewer was brought in to resolve the discrepancy. A
reviewer included an article if it addressed the provision of
prophylaxis in routine and/or sensitizing situations within
healthcare settings. Articles that explored dosage and/or
the administration of anti-D immunoglobulin practices
were excluded.
Potential sensitizing events
The authors define a sensitizing event in RhD negative
pregnant women as an event that leads to the development
of anti-D antibodies due to maternal-fetal blood exchange.
The following list of potential sensitizing events was
adapted from Urbaniak & Greiss’ [2] and incorporated
events listed in existing guidelines. The guidelines con-
sulted in this process were from the World Health
Organization, American Congress of Obstetricians and
Gynecologists in the United States (US), the National
Institute for Clinical Excellence in the United Kingdom
(UK), Australia’s National Blood Institute, the Society
of Obstetricians and Gynecologists of Canada, and the
British Committee for Standards in Haematology [5-9,16].
An additional file provides a list that summarizes all clin-
ical events considered at risk for sensitization in RhD
negative pregnant women because of the potential for
fetal-maternal hemorrhage as outlined in the aforemen-
tioned guidelines (see Additional file 1) [1].
Summarizing and reporting results
Each reviewer completed a data extraction form for each
article reviewed. The form included four predefined themes:
policy, practice, education, and research. The reviewers were
asked to provide comments regarding the articles’ contribu-
tion, challenges, or opportunities for each of the themes.
A narrative discussion was used to synthesize the studies
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categorized and summarized into a matrix: methodology,
geographic location, healthcare setting, number of partici-
pants, and if the study looked at the provision of anti-D
immunoglobulin for routine antenatal, routine postnatal,
and/or sensitizing events. An additional file provides the
matrix of included articles (See Additional file 2).
Results
The searches yielded 323 articles. After duplicates were
removed 301 articles remained. The screening process
weeded out 266 abstracts, leaving 35 articles for review.
Hand searching references of the 35 articles identified an-
other 13 articles for potential inclusion in the review. The
final reviewing process included a total number of 18 arti-
cles. The review process is illustrated in an additional file
using a flow chart (see Additional file 3).
Of the 18 articles included in the review, 13 were con-
ducted in the UK, two in Canada, one in Australia, one
in the US, and one review article. The settings included
maternity units, nurse led clinics, emergency departments,
and general practice clinics.
The majority, 15 articles, of the included studies are
retrospective cohort studies. There was only one prospect-
ive cohort study available. Of the retrospective studies 5
involved more than one institution, 7 articles were at one
institution, and two articles were not clear on the setting.
Of the 15 retrospective studies one utilized data from a
national reporting system.
Routine antenatal
According to the guidelines in the UK, Australia, Canada,
and the US, anti-D immunoglobulin should be given
routinely to RhD negative pregnant women [5,7-10].
The guidelines state that the prophylaxis may be given
in two injections at 28 and 34 weeks or in one injection at
28 weeks. Of the 18 articles, 8 explored adherence to
the delivery of routine antenatal anti-D immunoglobulin
[12,17-23]. Each article varied in the approach but the over-
all findings are that the delivery of anti-D immunoglobulin
in these routine situations is consistently delivered. The
figures ranged from 80 to 90% adherence. MacKenzie
et al’s [20] study found the timing of the delivery of
anti-D prophylaxis was an issue: “There was limited suc-
cess at providing prophylaxis at the correct gestation for
eligible women. Eighty-nine percent received one injec-
tion and 74% received both, but only 29% at the correct
gestation.” In a 2012 Canadian study, Koby et al. [12]
found that the routine postnatal delivery of anti-D im-
munoglobulin occurred 98.5% of the time, whereas the
antenatal delivery of the prophylaxis was suboptimal at
85.7%. The authors suggest that hospital-based protocol
systems lead to increased adherence in postnatal ad-
ministration [12]. The hospital-based protocol describedinvolves various checkpoints throughout labour and deliv-
ery. These checkpoints alert physicians and nurses to note
and deliver anti-D immunoglobulin (if needed) at admis-
sion, post-delivery, transfer to postpartum unit, and at
discharge [12]. The authors hypothesize that the adminis-
tration rate of antenatal anti-D immunoglobulin is lower
due to errors that may occur in physician-dependent
situations, such as failure to identify and treat RhD nega-
tive women and lack of protocols and/or team based
approaches [12].
Routine postnatal
The provision of anti-D immunoglobulin to RhD negative
women upon the delivery of an RhD positive infant should
occur within 72 hours [1]. The studies included in this re-
view found favourable results in this regard. The routine
provision of postnatal anti-D immunoglobulin was fairly
consistent across the studies. Studies found that RhD
negative women that delivered an RhD positive infant
were given anti-D immunoglobulin between 95-100% of
the time [12,19,24,25].
Sensitizing events
As defined earlier, potential sensitizing events can occur
at any time throughout the pregnancy and can have dev-
astating consequences. Out of the 18 articles included in
this review 8 articles examined the provision of anti-D
immunoglobulin when potential sensitizing events occur
[13,23,24,26-30].
The testing of RhD status is an integral step in the pre-
vention of RhD alloimmunization. In situations for which
potential sensitizing events present themselves preg-
nant women were often discharged without having their
RhD status tested. Further, pregnant women that were
discharged may have been RhD negative consequently
raising the opportunity for RhD alloimmunization to
occur. A retrospective study conducted in Canada in
1990 (prior to national guidelines), found that the RhD
status of pregnant women discharged from the emergency
department was performed in 86% of all the women dis-
charged [27]. A more recent study conducted in the US
found that 89% of women with potential sensitizing events
had their RhD status documented and/or tested [13]. A
small study exploring the effectiveness of a nurse practi-
tioner led early pregnancy clinic found that all RhD nega-
tive women presenting to the clinic had their RhD status
tested and received appropriate prophylaxis [26].
This review found that the provision of anti-D immuno-
globulin was low in situations for which potential sensitiz-
ing events occur. A recent US study found that although
89% had RhD status testing, only 54% of those that were
RhD negative actually received the prophylaxis and was
lower in second and third trimesters [13]. In an older
study conducted in the UK, adherence was looked at prior
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periencing potential sensitizing events based on available
guidelines at the time; in each instance the provision of
anti-D immunoglobulin was suboptimal [24]. For example,
in the second and third trimester “more than 25% of
women in the large maternity unit, and over 33% in the
smaller unit” did not receive anti-D immunoglobulin [24].
Gestational age appears to be a factor in the subopti-
mal provision of anti-D immunoglobulin. A retrospective
study looking at the management of women presenting
the emergency department prior to 12 weeks gestation
found that of 112 patients 97 were discharged without
having their RhD status tested [30]. A survey study con-
ducted in Australia found that general practitioners would
offer anti-D immunoglobulin in only 57% of cases of
threatened miscarriages [29]. The general practitioners
were also more likely to provide anti-D immunoglobu-
lin if the patient presented with heavy bleeding or if the
pregnancy was non-viable [29]. Interestingly, this study
found that in cases of threatened miscarriage, “rural doc-
tors were more likely than urban doctors to offer anti-D in
this situation (66% vs. 55%; difference, 11%; 95% CI, 1% to
22%)” [29]. An earlier study in the UK “found a significant
level of noncompliance with published recommendations
in relation to routine screening for antibodies, administra-
tion of anti-D immunoglobulin and Kleihauer testing”
[23]. Although this study is older and guidelines have
since changed, the findings suggest there was an issue
with the provision of anti-D immunoglobulin less than
20 weeks gestation [23].
Discussion
The literature provides evidence that there are opportun-
ities for quality improvement in the delivery of prophylaxis
in routine and clinically significant situations. RhD negative
women are not being consistently tested for their RhD sta-
tus in clinically significant situations and are consequently
not provided anti-D immunoglobulin when required. The
categories of practice, policy, education, and research were
chosen to discuss the results as it pertains to each category.
The attempt is to provide suggestions and guidance in each
domain.
Practice
There is a need for an increased efficiency with the
provision of anti-D immunoglobulin, particularly in
situations of potential sensitizing events. The existing
research provides the evidence that anti-D is not always
given at the right time or at all; although, in controlled en-
vironments such as maternity wards RhD negative women
are receiving prophylaxis post-delivery almost 100% of the
time.
Only two studies discussed the woman’s role in the deci-
sion to receive anti-D immunoglobulin [18,21]. In someinstances the women made well-informed decisions
based on their current health and relationship status. In
MacKenzie et al’s [21] study, they found a small number
of women increasingly denying prophylaxis in the 1990s.
The authors entertained the notion that this rise in refusal
of anti-D was attributed to “a growing anxiety about pos-
sible infection from the administration of blood products
during the decade, and such anxiety may well have been
exacerbated when the preparation previously used for
RhD prophylaxis was withdrawn because of concerns re-
lating to variant Creutzfeldt–Jakob disease transmission”
[21]. These results suggest that there is a need for im-
proved communication amongst health care providers
and RhD negative women, between departments (such as
laboratories and emergency departments), and between
health care providers involved in the continuum of care.
The studies included in this review span twenty-two
years, the earliest study dating back to 1992. The last ten
years has seen only six studies addressing this topic des-
pite recent guideline development and implementation
[12,13,17,18,21,31]. These five studies (and one review)
continue to find opportunities for improved management
of RhD negative pregnancies, particularly in situations for
which sensitizing events occur. Guidelines on the preven-
tion of RhD alloimmunization do not provide strong rec-
ommendations for situations involving sensitizing events,
particularly in the first trimester. This is a result of a
paucity of evidence regarding the effectiveness of anti-
D immunoglobulin in the first trimester after a sensitizing
event [16,32]. This lack of evidence is one of the reasons
guidelines are lacking strong recommendations. Conse-
quently, the delivery of anti-D immunoglobulin continues
to be problematic and quality improvement remains
suboptimal.
Few studies provide recommendations for an improve-
ment in the delivery of anti-D immunoglobulin. The most
recent Canadian study suggests that improved communi-
cation and patient education for RhD negative pregnant
women would potentially improve adherence. The same
study suggests that a checklist system, such as the one de-
scribed in the results section discussing post-natal admin-
istration of anti-D immunoglobulin would be helpful in
antenatal situations. A team-based approach involving
nurses with specific checklists in place and/or a clinic
specific to the administration of anti-D immunoglobulin
are other recommendations put forth by Koby et al. [12].
These suggestions need to be integrated into the manage-
ment of RhD negative pregnancies both in hospital and
primary care settings. These interventions need to be eval-
uated for effectiveness and quality improvement.
Policy
The longest retrospective study of 15 years conducted
in the UK, provides data that there has been consistent
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globulin [17]. This study is important because it covers
a lengthy period of time in reporting of anti-D immuno-
globulin mismanagement but it also covers the period
of guideline implementation. Throughout the 15 years
of reporting new guidelines were disseminated. Despite
the new guidelines mismanagement continued to occur.
Perhaps continued issues are due to an increase in health-
care providers reporting or a lack of uptake or clarity of
the guidelines, but nevertheless an issue regarding the de-
livery of anti-D immunoglobulin still occurred. Inevitably
there is room for improvement in the delivery of anti-D
immunoglobulin and the need for clearer guidelines with
implementation plans and evaluation to ensure the uptake
of evidence.
In several studies conducted in acute care settings,
such as emergency departments, pregnant women with
potential sensitizing events did not receive optimal care.
This suggests that there are opportunities for this clinical
setting to develop interventions that perhaps integrate
RhD testing and the increased delivery of anti-D in clinic-
ally significant potential sensitizing situations. The oppor-
tunity for quality improvement in the management of
RhD negative pregnancy is imperative.
Education
Thorpe’s review article is an example of an educational
attempt to improve the quality of care for RhD negative
pregnant women with a focus on blunt trauma [31]. In
Nova Scotia there is an active continuing medical educa-
tion program and reporting system for RhD negative
pregnancies [33]. These two examples provide strategies
for continued education in this area. Based on the results
of this review continued education should focus on routine
antenatal and potential sensitizing situations. In addition,
continued education regarding communication would help
to improve the quality of care by ensuring the issues re-
lated to mismanagement are not caused by communication
factors. An Australian study found that rural physicians
were more likely to deliver anti-D immunoglobulin in situ-
ations of threatened miscarriages than urban physicians
[29]. Although the definition of rural is not provided and
the study is a self-reported survey of individual practices,
an exploration into what aspects of rural practice and/or
education that lead to the increased provision of anti-D in
situations of threatened miscarriage by rural physicians
would be helpful.
The definition of shared-care states that patients are
provided with the opportunity to engage and collaborate
in health care decision-making [34]. Only two studies
mentioned the role of RhD negative women in the man-
agement of their pregnancy [18,21]. The limited literature
in this area requires further exploration. Shared care
and patient engagement literature provides evidence thatpatients require knowledge and information in order to
engage in their care. Therefore, it is suggested that women
need to be informed of their blood type, perhaps prior to
pregnancy, and educated about RhD factor and the risks
that lie therein.
Research
The retrospective cohort methodology is an appropriate
method in researching the use of anti-D immunoglobulin
in clinical settings [35]. It would be helpful to have more
studies utilizing population-based data, large multi-center
studies involving prospective approaches or retrospective
approaches, and more studies in Canada, Australia, and
the US. Further research is required to understand the
factors associated with suboptimal provision of anti-D
immunoglobulin in situations where potential sensitizing
events occur. As Koby et al. [12] suggest, errors of omis-
sion can occur in situations where the decisions are
physician-dependent. However, only one study provided
the factors involved in the omission of or late adminis-
tration of anti-D immunoglobulin [17]. The factors in-
volved poor documentation, misinterpretation of laboratory
results, issues with storage of the prophylaxis, and commu-
nication between departments. In addition, a better under-
standing of women’s knowledge and experiences with RhD
negative pregnancies and its possible implications would
provide further insight into RhD alloimmunization. Once
there is a basic understanding interventions may be devel-
oped and trialed for effectiveness.
Limitations
The limitations of this scoping review lie within the lit-
erature retrieved and included. The studies included span
across several decades with the first article published in
1992 [27]. In addition, these included studies have been
conducted in four different countries. The majority of arti-
cles were conducted in the UK. This means that the
results of these studies are not necessarily generalizable
across various countries, amongst varying clinical guide-
lines, with current clinical guidelines, and within different
settings. Due to these limitations conducting a further
systematic review of the literature is not recommended.
Conclusions
The included articles offer a glimpse into the management
of RhD negative pregnancies in various countries with
existing national guidelines. The existing evidence indi-
cates an opportunity for quality improvement in situations
where potential sensitizing events are not at routine times
in pregnancy, such as miscarriage or fetal demise early in
pregnancy. Routine care for the prevention of RhD alloim-
munization in pregnancy and postpartum appears to be
fairly consistent. The paucity of recent literature in this
area leads to a recommendation for further research.
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